Publications by authors named "Ellen N Model"
Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.
Arthritis Rheumatol
January 2025
Article Synopsis
- Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis, and the study investigates the role of soluble CD13 (sCD13) and its signaling through the bradykinin receptor B1 (B1R) in SSc pathogenesis.
- Researchers found elevated levels of CD13, B1R, and MMP14 in skin from SSc patients, which contributed to fibrosis through signaling pathways activated by TGF-β and sCD13.
- The study concludes that targeting the sCD13-B1R axis could represent a novel and effective therapeutic strategy for treating skin fibrosis in SSc.
Article Synopsis
- * The study identifies the bradykinin receptor B1 (B1R) as the GPCR responsible for sCD13's effects on arthritis and shows that B1R is highly expressed in the synovial tissue of rheumatoid arthritis patients.
- * Blocking B1R reduced inflammation in various mouse models of arthritis and suggested that targeting B1R could be a promising treatment approach for rheumatoid arthritis and similar inflammatory conditions.
Binding of the bromodomain and extraterminal domain proteins (BETs) to acetylated histone residues is critical for gene transcription. We sought to determine the antifibrotic efficacy and potential mechanisms of BET inhibition in systemic sclerosis (SSc). Blockade of BETs was done using a pan-BET inhibitor, JQ1; BRD2 inhibitor, BIC1; or BRD4 inhibitors AZD5153 or ARV825.
View Article and Find Full Text PDFGlycoprotein nonmetastatic melanoma protein B (GPNMB) is involved in various cell functions such as cell adhesion, migration, proliferation, and differentiation. In this study, we set forth to determine the role of GPNMB in systemic sclerosis (SSc) fibroblasts. Dermal fibroblasts were isolated from skin biopsies from healthy subjects and patients with diffuse cutaneous (dc)SSc.
View Article and Find Full Text PDF